Ikeda Satoshi, Funakoshi Naoya, Suzuki Keiko
Department of Pathology, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan.
Acta Cytol. 2009 Jan-Feb;53(1):29-35. doi: 10.1159/000325082.
To investigate immunochemical markers of assisting cytologic diagnosis to evade the inaccuracy to be caused by alteration of urinary samples.
We used p53 and epidermal growth factor receptor (EGFR) in an immunostaining cocktail for the differential diagnosis of urine cytology. We reviewed urothelial tumor tissues resected from 36 cases, normal urothelium tissues collected from 20 autopsy cases and 108 separate urine samples.
No positive case was obtained from the autopsy cases. In 20 of the cancer cases treated by transurethral resection, the average positive rates of EGFR and p53 cells were 69% and 12%, respectively. As for the urine smears, positive findings were observed in atypical cells in 20 of 21 cytologically positive cases (95%), which were also confirmed to be malignant in histologic examinations. In contrast, color development was observed in urothelial cells from only 9 of 87 cases (10%), which were unclear for atypia and judged benign, though 5 of those 9 specimens were from patients with a previous history of urothelial cancer. In 2 of those 5 cases, recurrences were confirmed later.
For urine cytology, we found that our cocktail immunostaining method was useful for the differential diagnosis.
研究辅助细胞学诊断的免疫化学标志物,以避免尿样改变导致的诊断不准确。
我们使用p53和表皮生长因子受体(EGFR)的免疫染色混合液进行尿细胞学的鉴别诊断。我们回顾了36例切除的尿路上皮肿瘤组织、20例尸检病例收集的正常尿路上皮组织以及108份单独的尿样。
尸检病例中未获得阳性病例。在20例经尿道切除术治疗的癌症病例中,EGFR和p53细胞的平均阳性率分别为69%和12%。对于尿涂片,21例细胞学阳性病例中的20例(95%)在非典型细胞中观察到阳性结果,这些病例在组织学检查中也被证实为恶性。相比之下,87例病例中只有9例(10%)的尿路上皮细胞出现显色,这些细胞非典型性不明确且判断为良性,尽管这9份标本中有5份来自既往有尿路上皮癌病史的患者。在这5例中的2例中,后来证实有复发。
对于尿细胞学检查,我们发现我们的混合免疫染色方法有助于鉴别诊断。